EVER Pharma acquires Amneal Deutschland GmbH and extends its commercial presence in Europe
17.5.2019 10:25:00 EEST | Business Wire | Press release
EVER Pharma Holding Ges.m.b.H (Austria) announced today that it has completed the acquisition of Amneal Deutschland GmbH, a subsidiary of Amneal Pharmaceuticals that operates the company's commercial operations in Germany. Amneal Deutschland already distributes several EVER Pharma products in Germany and is a strongly established player in the German hospital market. The acquired entity will be rebranded to EVER Pharma GmbH.
“This acquisition represents another milestone in the expansion of EVER Pharma’s commercial footprint in Europe. With this new operation, EVER Pharma extends its portfolio in Germany and establishes a solid platform for the growth of its portfolio and pipeline” commented Georges Kahwati, General Manager of EVER Pharma.
“We are pleased to establish another EVER affiliate in one of the key European markets in line with our strategy of establishing our own business presence in core markets.” added Julia Hillebrand, Managing Director and Owner.
About EVER Pharma:
EVER Pharma is a fully integrated specialty pharmaceuticals company focused on the research, development, production and commercialization of products in the areas of neurology, critical care, anesthesia and oncology. EVER Pharma markets in over 70 countries through wholly owned affiliates and distribution partners.
###
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190516006191/en/
Contact information
To learn more about this acquisition:
Norbert Hittenberger
EVER
Valinject GmbH
Phone: +43 7665 20555 860
Mobile: +43 664 80964
860
eMail: Norbert.Hittenberger@everpharma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Empire State Building Presents First-Ever Children’s Birthday Party Package for Celebrations at the Iconic Observatory Experience23.2.2026 16:13:00 EET | Press release
Parents who have looked for the best birthday party idea for their children have had their wish fulfilled. Today, the Empire State Building (ESB) announced the debut of its first-ever ESB Birthday Party Package for kids at the international icon’s Observatory as part of year-long 95th anniversary celebrations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223161708/en/ The Empire State Building Presents First-Ever Children’s Birthday Party Package for Celebrations at the Iconic Observatory Experience “From Lego playtime to Percy Jackson readers, children love the Empire State Building and now parents can give an unmatched experience to their children and their friends,” said Anthony E. Malkin, chairman and CEO of Empire State Realty Trust. “This birthday party package tops them all with an escorted visit through our world-famous Observatory, a private party room with a Ghirardelli sundae chef, Empire State Building party
CoolMPS™ 600: Accurate and Affordable Long MPS/NGS Reads on a Mid-Throughput Platform23.2.2026 16:00:00 EET | Press release
Swiss Rockets AG announces that its CoolMPS 600 mid-throughput sequencer with advanced chemistry and novel MPS/NGS read length will become available in Q2 2026. Enabled by its exclusive license of CoolMPS technology, Swiss Rockets AG is developing its first sequencer, CoolMPS 600, through contract R&D with Complete Genomics since August 2025. The platform is utilizing the company’s proprietary antibody-based CoolMPS™ chemistry combined with DNBSEQ™, a real PCR-free DNA nanoarray technology. Separately, Swiss Rockets AG announced that it has entered into a definitive agreement to acquire 100% ownership of Complete Genomics. CoolMPS 600 enables cost-effective extended single-end sequencing to 600 bases (SE600) while maintaining high base accuracy. The system is designed to support advanced whole-genome sequencing (WGS) with improved mapping accuracy across complex genomic regions, including better detection of structural variants. It also enables full length transcriptomes and more infor
Xsolla Co-Sponsors Gamescom Dev Leadership Summit in Lisbon, Bringing Together Gaming Industry Leaders to Shape the Future of Game Development23.2.2026 16:00:00 EET | Press release
Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced its co-sponsorship of the Gamescom Dev Leadership Summit Lisbon, taking place February 24-26 at SUD Lisboa in Portugal. The event brings together gaming industry executives, studio founders, and business leaders to explore opportunities and innovations shaping the future of game development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223253705/en/ Graphic: Xsolla As part of its sponsorship, Xsolla will host the summit's Wednesday evening networking dinner and co-moderate a strategic roundtable session focused on business models and sustainable growth in the gaming industry. "We're seeing incredible innovation from studios across Europe as they build more direct relationships with their players and explore new ways to grow their businesses," said Berkley Egenes, Chief Marketing & Growth Officer at
Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic Epilepsies23.2.2026 15:08:00 EET | Press release
Angelini Pharma, part of the privately owned Angelini Industries, and Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for the treatment of central nervous system (CNS) disorders, announced today that they have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies. The collaboration brings together Quiver’s unique drug discovery capabilities, data assets, and AI models with Angelini Pharma’s established expertise in brain health and epilepsy drug development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223465174/en/ Under the terms of the multi-year agreement, Quiver will receive an undisclosed advance payment and support for defined research activities along with additional licensing fees granting Angelini Pharma exclusive access to collaboration-generated data during the research term. Quiver is also eligible to receiv
Armis Achieves U.S. Department of Defense Impact Level 5 Authorization23.2.2026 15:00:00 EET | Press release
Armis, the cyber exposure management & security company, today announced that it has achieved authorization from the U.S. DoD’s Defense Information Systems Agency (DISA) to operate at an Impact Level 5 (IL5). This means that Armis has met strict requirements to manage and secure the DoD’s critical infrastructure, including Controlled Unclassified Information (CUI) systems. “We are committed to helping Federal agencies like the Department of Defense address their toughest cybersecurity challenges,” said Alex Mosher, President and CRO at Armis. “Achieving DISA IL5 authorization is an important milestone for Armis as we continue to support DoD customers in safeguarding critical systems, sensitive data and national security infrastructure from evolving cyber threats.” Armis empowers Federal agencies to build and optimize comprehensive cybersecurity programs with Armis Centrix™, the FedRAMP and DISA IL authorized Cyber Exposure Management Platform. The company previously achieved FedRAMP Mo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom